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Abstract
Purpose—An examination of multiple primary cancers can provide insight into the etiologic role 
of genes, the environment, and prior cancer treatment on a cancer patient’s risk of developing a 
subsequent cancer. Different rules for registering multiple primary cancers (MP) are used by 
cancer registries throughout the world making data comparisons difficult.
Methods—We evaluated the effect of SEER and IARC/IACR rules on cancer incidence rates and 
trends using data from the SEER Program. We estimated age-standardized incidence rate (ASIR) 
and trends (1975–2011) for the top 26 cancer categories using joinpoint regression analysis.
Results—ASIRs were higher using SEER compared to IARC/IACR rules for all cancers 
combined (3 %) and, in rank order, melanoma (9 %), female breast (7 %), urinary bladder (6 %), 
colon (4 %), kidney and renal pelvis (4 %), oral cavity and pharynx (3 %), lung and bronchus 
(2 %), and non-Hodgkin lymphoma (2 %). ASIR differences were largest for patients aged 65+ 
years. Trends were similar using both MP rules with the exception of cancers of the urinary 
bladder, and kidney and renal pelvis.
Conclusions—The choice of multiple primary coding rules effects incidence rates and trends. 
Compared to SEER MP coding rules, IARC/IACR rules are less complex, have not changed over 
time, and report fewer multiple primary cancers, particularly cancers that occur in paired organs, at 
the same anatomic site and with the same or related histologic type. Cancer registries collecting 
incidence data using SEER rules may want to consider including incidence rates and trends using 
IARC/IACR rules to facilitate international data comparisons.
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Introduction
According to the International Agency for Research on Cancer (IARC), over 14 million new 
cases of cancer were diagnosed worldwide in 2012, the most recent year for which data are 
available [1]. The most commonly diagnosed cancers were those of the lung and bronchus, 
female breast, colorectum, and prostate. Incident cases worldwide are projected to increase 
to over 22.2 million by 2030 due primarily to rapid population growth and aging [2]. Cancer 
control strategies are urgently needed to address the growing cancer burden. To this end, 
population-based cancer registries serve a vital role by providing information necessary for 
directing and monitoring cancer control activities and health policy initiatives [3].
Much time and effort have been spent on standardizing the collection, consolidation, 
analysis, and reporting of cancer surveillance data to ensure that these data are high quality, 
complete, and suitable for comparisons within the USA [4, 5], North America [6], among 
countries worldwide [7–11]. In the mid-1970s, around the start of the Surveillance, 
Epidemiology, and End Results (SEER) Program [12], coding rules were developed to 
enumerate primary cancers including differentiating a new primary cancer from a distant 
metastasis or a recurrent cancer [13]. These rules have been revised over time with the most 
recent changes implemented in 2007 and are used by cancer registries throughout North 
America. In 2004, a working group comprised of individuals representing IARC, the 
International Association of Cancer Registries (IACR), and the European Network of Cancer 
Registries updated and published multiple primary coding rules previously developed by 
IACR [14]. The IARC/IACR rules are predominately used by cancer registries outside North 
America and have not been modified since their publication in 2004. Compared to SEER 
multiple primary coding rules, IARC/IACR rules are less complex, have not changed over 
time, and report fewer multiple primary cancers, particularly cancers that occur in paired 
organs, at the same anatomic site and with the same or related histologic type [15].
To address issues of comparability, IARC developed an algorithm that can be used to 
identify multiple primary cancers defined according to IARC/IACR rules among primary 
cancer cases whose data were originally collected and consolidated using less conservative 
rules such as the SEER rules [16]. This program is used to process cancer data from North 
America for inclusion in Cancer Incidence in Five Continents [10], GLOBOCAN [11], and 
for the inclusion of survival data in CONCORD studies [7, 8] and the International Cancer 
Benchmarking Partnership [9].
Differences in coding practices used to collect and consolidate multiple primary cancers can 
result in differences in incidence rates and trends [17, 18]. The importance of this issue is 
likely to grow as increasingly more cancer patients are living longer following a diagnosis of 
cancer [5] and are thus at greater risk of being diagnosed with a subsequent cancer [19]. To 
date, variations in breast cancer incident counts have been examined using SEER and IARC/
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IACR multiple primary coding rules [20] and the impact of these rules has been assessed on 
cancer survival [21]. In this paper, we examine the effect of these two widely used multiple 
primary coding rules on incidence rates and trends for leading cancers using a common 
dataset.
Materials and methods
Source of data
Cancer incidence data for patients diagnosed 1975 through 2011 were obtained from nine 
population-based cancer registries participating in the SEER Program in five states 
(Connecticut, Hawaii, Iowa, New Mexico, Utah) and four metropolitan areas (Atlanta, 
Detroit, San Francisco-Oakland, Seattle) covering approximately 10 % of the US population 
[5]. These registries were selected because they have been in operation for more than 35 
years and will have more information (i.e., past cancer diagnoses) with which to correctly 
identify a prior cancer than registries that have been in operation for fewer years [22]. Data 
were collected and reported using standard codes and procedures [23] and according to the 
SEER multiple primary coding rules in use at the time of diagnosis [13]. The primary site 
and histology of each cancer were coded according to the International Classification of 
Diseases for Oncology (ICD-O) edition in use at the time of diagnosis, converted to the third 
edition, and classified according to the SEER site recodes [24]. In situ urinary bladder 
cancers were considered invasive for the purpose of reporting incidence data in the SEER 
Program [25].
In order to compare case counts, incidence rates and trends by using different multiple 
primary cancer coding rules, we looked at first primary cancers [only primary cancer 
diagnosed in a patient (sequence number: 00) or first primary cancer of multiple primary 
cancers diagnosed in a patient (sequence number: 01)] according to SEER rules and the 
additional number (if any) of primary cancers diagnosed in a patient (sequence number: 
02+) according to SEER and IARC/IACR rules, respectively.
Analysis
Age-standardized incidence rates (ASIR) per 100,000 persons adjusted to the 2000 the US 
standard population [26] and corresponding 95 % confidence intervals (95 % CI) were 
generated for all sites combined and for 26 leading site categories using SEER*Stat software 
(version 8.0.4) [27]. This version of the software contains a feature whereby invasive 
multiple primary cancers collected using SEER multiple primary rules can be re-classified 
according to IARC/IACR rules.
ASIR ratios (SEER: IARC/IACR) were generated for cases diagnosed 2005–2009. We 
restricted cases to this 5-year time period to maximize the operational length of the registries 
(to identify multiple primary cancers) while allowing at least 3 years between the time a 
patient was diagnosed and when their data were submitted to the SEER Program to 
maximize case ascertainment (and mitigate reporting delays) [28]. As there is no formal 
statistical test to compare incidence rates on the same population by using different case 
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definitions methods, ratios were noted where the 5-year point estimate for the IARC/IACR 
rate was not contained within the corresponding 95 % CI of the SEER rate.
Trends in ASIRs were analyzed using joinpoint regression which involved fitting a series of 
joined straight lines on a logarithmic scale to the trends in the annual ASIRs [29]. A 
maximum of five line segments were allowed in the models for the period 1975 through 
2011. We described the resulting trends by the slope of each line segment as the annual 
percent change (APC), using t tests (two-sided, p < 0.05) to assess whether the APCs were 
statistically significantly different from zero [30]. We used the terms increase or decrease to 
describe significant trends and stable to describe nonsignificant trends.
Results
Figure 1 shows the number of primary cancers that were reported as a first primary cancer 
according to SEER multiple primary coding rules and the number and percentage of 
additional cases reported as multiple primary cancers according to IARC/IACR and SEER 
rules between 1975 and 2011. In 1975, 62,136 cases of first primary cancer were reported. 
An additional 4,805 (7.2 %) cases were reported as multiple primary cancers according to 
IARC/IACR rules and 5,222 (7.8 %), or an additional 422 cases, according to SEER rules. 
By 2011, 16.7 % of cases were reported as multiple primary cancers according to IARC/
IACR rules and 19.7 %, or an additional 5,059 cases, according to SEER rules.
ASIRs for patients diagnosed 2005 through 2009 (Table 1), as shown by the rate ratio, were 
higher using SEER rules compared to incidence rates using IACR rules for all cancer sites 
combined (ASIR 1.03 %, or 3 %) and eight site-specific cancers: in rank order, melanoma 
(9 %), female breast (7 %), urinary bladder (6 %), colon (4 %), kidney and renal pelvis 
(4 %), oral cavity and pharynx (3 %), lung and bronchus (2 %), and non-Hodgkin lymphoma 
(2 %). Rate ratios increased with increasing age at diagnosis and were largest for patients 65 
years of age and older: in rank order, melanoma (13 %), female breast (10 %), urinary 
bladder (6 %), colon (5 %), kidney and renal pelvis (5 %), oral cavity and pharynx (5 %), 
lung and bronchus (3 %), and non-Hodgkin lymphoma (3 %). ASIRs did not differ for all 
ages combined or by age group for Hodgkin lymphoma, myeloma, leukemia, mesothelioma, 
or Kaposi sarcoma, or for cancers of the esophagus, rectum and rectosigmoid junction, 
stomach, liver and intrahepatic bile duct, pancreas, larynx, cervix uteri, corpus uterine, 
ovary, prostate, testis, brain and other nervous system, or thyroid.
Table 2 shows the trends in ASIRs between 1975 and 2011 by cancer site for first primary 
cancers and for all cancers combined (first and multiple primary cancers) using the SEER 
and IARC/IACR rules, respectively. The cancer sites selected for comparison were all 
cancers combined and the eight cancer site groups noted in Table 1 to have different ASIRs 
according to SEER versus IARC/IACR rules.
Incidence rates for all cancers combined increased (1.2 % per year) between 1975 and 1989, 
were stable between 1989 and 1998, declined (0.3 and 0.4 % per year) between 1998 and 
2009, and were stable through 2011, using SEER and IARC/IACR rules. Rates of first 
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cancers (all sites combined) increased (0.8 % per year) between 1975 and 1989, were stable 
between 1989 and 1999, and declined (1.0 % per year) through 2011.
Incidence rates for oral cavity and pharynx cancers were stable between 1975 and 
1979/1981, decreased (1.1 % per year) through 2003, and were stable through 2011, using 
SEER and IARC/IACR rules. Incidence rates for first oral cancers were stable between 1975 
and 1984, decreased (1.7 % per year) through 2001, and were stable through 2011.
Incidence rates of colon cancer increased (1.2 % and 1.0 % per year) between 1975 and 
1985, decreased (1.7 % per year) between 1985 and 1995, were stable between 1995 and 
1998/2000, and decreased (2.4 or 2.7 and 5.3 or 4.9 % per year, respectively) through 2011, 
using SEER and IARC/IACR rules. Incidence rates of first colon cancers increased (0.6 % 
per year) between 1975 and 1985, decreased (2.1 % per year) through 1995, were stable 
through 2001, and declined (3.4 % per year) through 2011.
Incidence rates for cancers of the lung and bronchus increased (2.5 and 0.9 % per year) 
between 1975 and 1991 and declined (0.7 and 2.6 or 2.8 % per year, respectively) through 
2011, using SEER and IARC/IACR rules. Incidence rates for first cancers of the lung and 
bronchus increased (1.7 % per year) between 1975 and 1984, were stable between 1984 and 
1991, and decreased (1.4 and 3.7 % per year) through 2011.
Melanoma incidence rates increased (5.7 and 2.9 or 2.7 % per year, respectively) between 
1975 and 2005/2006 using SEER and IARC/IACR rules. Between 2005 and 2011, 
melanoma incidence rates increased (1.3 % per year) using SEER rules and were stable 
between 2006 and 2011 using IARC/IACR rules. Between 1975 and 2011, incidence rates of 
first melanoma cancers increased (4.4 and 1.8 % per year).
Female breast cancer incidence rates were stable between 1975 and 1981, increased (4.0 and 
3.7 % per year, respectively) between 1980 and 1987, were stable between 1987 and 1994, 
increased (1.8 and 1.6 % per year, respectively) between 1994 and 1999, decreased (2.3 % 
per year) between 1999 and 2004/2005, and were stable through 2011 using SEER and 
IARC/IACR rules. First female breast cancers were stable between 1975 and 1980, 
increased (3.6 % per year) through 1987, were stable between 1987 and 1994, increased 
(1.6 % per year) between 1994 and 1999, and were stable through 2011.
Urinary bladder incidence rates increased (0.7 % per year) between 1975 and 1986/1987 
using SEER and IARC/IACR rules. Incidence increased (0.2 % per year) between 1986 and 
2007 and decreased (1.6 % per year) through 2011 using SEER rules. Urinary bladder 
incidence rates were stable between 1987 and 2011 using IARC/IACR rules. The incidence 
of first urinary bladder cancer was stable between 1975 and 1987 and decreased (0.7 and 
2.7 % per year) through 2011.
Kidney and renal pelvis cancer incidence rates increased (2.3 % per year) between 1975 and 
1994, were stable between 1994 and 1997, increased (3.1 % per year) between 1997 and 
2008, and were stable through 2011, using SEER rules. Kidney cancer incidence rates 
increased (1.9 and 3.3 % per year) between 1975 and 2008 and were stable through 2011 
using IARC/IACR rules. Incidence rates of first kidney cancer increased (1.7 % per year) 
Weir et al. Page 5
Cancer Causes Control. Author manuscript; available in PMC 2018 March 14.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
between 1975 and 1994, were stable between 1994 and 1997, increased (2.7 % per year) 
between 1997 and 2008, and were stable through 2011.
The incidence of non-Hodgkin lymphoma (NHL) increased (3.7 and 0.5 % per year) 
between 1975 and 2011 using SEER rules. Incidence increased (3.6 and 0.6 % per year) 
between 1975 and 2007 and decreased (1.8 % per year) between 2007 and 2011 using IACR 
rules. The incidence of first NHL increased (3.2 % per year) between 1975 and 1991, 
stabilized between 1991 and 2009, and decreased (4.4 % per year) through 2011.
For the cancers presented in Table 2, Fig. 2a–i shows the observed and joinpoint modeled 
ASIRs between 1975 and 2011 for first primary cancers and for all (first and multiple) 
primary cancers combined using SEER and IARC/IACR coding rules, respectively, for all 
sites combined and for select cancers.
Discussion
This study provided a unique opportunity to evaluate the effect of two widely used multiple 
primary cancer coding rules on cancer incidence rates and trends using a common dataset. 
Incidence data from nine population-based cancer registries participating in the SEER 
Program were collected using the SEER multiple primary rules in use at the time of 
diagnosis and analyzed according to both SEER and IARC/IACR rules. The SEER 9 
registries were selected because their annual data submissions must meet SEER Program 
standards with respect to the completeness and quality of their data and because the 
operational length of these registries affords the opportunity for more accurate and complete 
counting of subsequent primaries [5]. As has been noted [22], the proportion of cancer 
patients with a known prior cancer will depend on the length of operation of the cancer 
registry: Cancer registries that have been in operation for many years will have more 
information (i.e., past cancer diagnoses) with which to correctly identify a prior cancer than 
a cancer registry that has been in operation for fewer years. Thus, the differences between 
the age-standardized incidence rates and trends for a given cancer site reflect the differential 
impact that these coding rules have on enumerating the number of primary cancers 
diagnosed in a cancer patient.
Incidence rates using SEER multiple primary coding rules were higher compared to 
incidence rates using IARC/IACR rules for all cancers combined and for many of the 
leading cancers including the most commonly diagnosed cancers worldwide: female breast, 
lung and bronchus, and colon cancers. This reflects the fact that SEER rules generally allow 
more multiple cancers to be reported at the same anatomic site and with the same or related 
histologic type [15]. For example, under the SEER rules each subsite of the colon or each 
subsite of the skin for melanoma is considered its own separate primary site. In addition, the 
SEER rules consider the laterality of the tumor in the determination of multiple primary 
cancers and include a timing rule whereby a second cancer of the same histology in the same 
cancer site would be considered a second primary. While the IARC/IACR rules do make 
recommendations for incorporating laterality and cancer subsite in determining multiple 
primary cancers for colon and melanoma of the skin [14], the existing IARC/IACR 
algorithm does not take this into consideration [16] as many registries outside the USA do 
Weir et al. Page 6
Cancer Causes Control. Author manuscript; available in PMC 2018 March 14.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
not follow these recommendations. The SEER rules thus typically result in the reporting of 
larger case counts and incidence rates for cancers occurring among paired organs (female 
breast, kidney, lung and bronchus), organs with large surface areas [skin (i.e., melanoma), 
urinary bladder, colon, lung and bronchus, oral cavity and pharynx, kidney and renal pelvis], 
and with the same or related histologic types (non-Hodgkin lymphoma).
Interpreting the effect of multiple primary coding rules on incidence trends is more difficult. 
Trends in incidence rates, which include all primary cancers regardless of the order in which 
they are diagnosed, have generally been interpreted as reflecting changes in etiologic risk 
factors operating at the population level or the impact of screening, rather than the choice of 
the rules used to enumerate primary cancers. For example, long term declines in incidence 
rates for cancers of the lung and bronchus and oral cavity and pharynx parallel to that of a 
long-term reduction in the use of tobacco [31] while the recent increase in oral cancer, 
primarily among white males, may be attributed to human papillomavirus infections [32]. 
Improved and/or expanded screening may partially explain the recent declines in colon 
cancer [33] and the long-term increase in female breast cancer incidence rates seen in the 
USA [34] and worldwide [35]. Because screening can advance the detection of a pre-
invasive or preclinical cancer, screening can also alter the sequence in which two or more 
primary cancers are diagnosed in a patient or even if a cancer is diagnosed. The introduction 
of the PSA test in the late 1980s [36] may have led to the over diagnosis of prostate cancer 
in approximately 29 % of white men and 44 % of black men whose cancers were detected 
by PSA screening between 1988 and 1998 in the USA [37]. More recently, it has been 
estimated that as much as 20 % of female breast cancers detected through a population-
based screening study in Ontario might never have caused clinical symptoms or death within 
the woman’s lifetime [38].
To help facilitate the interpretation of the effect of multiple primary coding rules on trends in 
incidence rates, we included trends for first primary cancers (i.e., first of multiple cancers or 
the only primary cancer diagnosed in a patient) as these trends tend to reflect the impact of 
changes in the underlying risk of being diagnosed with cancer. The present study showed 
that trends in incidence rates, which include all primary cancers, were similar for the most 
part whether using SEER or IARC/IACR multiple primary coding rules and tended to mirror 
the incidence of first cancers, thus reflecting the impact of either changes in underlying risk 
factors, diagnostic intensity or early detection related to screening. The choice of multiple 
primary coding rules appeared to have little impact on trends in incidence rates for all 
cancers combined and for the majority of cancers investigated herein with the exception of 
cancers of the urinary bladder, and kidney and renal pelvis. This is not surprising because 
the majority of multiple primary cancers tend to arise in separate organ systems and would 
thus be counted as separate primaries under either set of rules [19]. Cancers of the urinary 
system, on the other hand, tend to be more multifocal in nature and are therefore at greater 
susceptibility to differences in the way they are counted.
Both SEER and IARC/IACR rules include specific guidelines for designating cancer that 
should be considered as arising in the same anatomic site. According to SEER rules prior to 
200 [7, 13], cancers of the renal pelvis and kidney should be considered one site, whereas 
cancers of urinary bladder should be considered a different site. However, according to the 
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IARC/IACR rules, cancers of the renal pelvis and urinary bladder should be considered one 
site, whereas cancers of kidney should be considered a different site. In 2007, the SEER 
rules changed to group cancers of the bladder and renal pelvis together as they are both 
predominately made of transitional epithelial where multifocal tumors tend to occur and 
because it is thought there is a greater possibility of tumor spread from a single clone to 
several sites [39]. Further complicating a comparison of cancers of the urinary system is the 
fact that both sets of rules (SEER and IARC/IACR) incorporate cancer site differences into 
the multiple primary determination process. Assigning of the cancer sites therefore will 
depend on the order in which cancers of the urinary system are diagnosed. Consider the 
following three examples: If a patient had a first primary renal pelvis cancer followed by a 
urinary bladder cancer, the patient would be considered to have two primary cancers 
according to SEER rules prior to 2007, but only one cancer (renal pelvis) according to 
IARC/IACR rules and current SEER rules. If a second patient had a first primary urinary 
bladder cancer followed by a renal pelvis cancer, the patient would also be considered to 
have two primary cancers according to previous SEER rule, but one cancer (urinary bladder) 
according to IARC/IACR rules and current SEER rules. Finally, if a third patient had a renal 
pelvis cancer and a urinary bladder cancer diagnosed simultaneously, that patient would also 
have two primary cancers according to previous SEER rules, but only one cancer (urinary 
system, NOS) to according to IARC/IACR rules and current SEER rules and, therefore, not 
counted as either a kidney and renal pelvis cancer or a urinary bladder.
Unlike the IARC/IACR rules, SEER multiple primary coding rules have changed over time, 
including the introduction around 1979 of a time interval used to distinguish synchronous 
cancers (e.g., cancers diagnosed at the same time or within 2 months) and metachronous 
cancer (e.g., cancer diagnosed more than 2 months apart) which allowed for cancers of the 
same histologic type and occurring at the same anatomic site to be considered as two 
primaries, and the introduction around 2007 of terms (multifocal and multicentric) used to 
enumerate cancers occurring at the same anatomic site and in close proximity (i.e., urinary 
bladder and renal pelvis). Because SEER registries collected data according to the multiple 
primary rules in use at the time of diagnosis, a change in the rules for reporting multiple 
primary cancers could affect trends in incidence rates, including incidence rates for first 
cancers. This may help explain the decline in the incidence rate of first primary kidney and 
renal pelvis cancers seen around 2007.
The differential impact of multiple primary coding rules on incidence rates and trends is 
likely to grow as the number and percentage of multiple primary cancers continues to 
increase as shown in the SEER data (Fig. 1). This increase reflects the fact that the risk of 
being diagnosed with cancer generally increases with age, and over the past several decades, 
the US population, like many populations worldwide, has grown particularly in the older age 
groups [40]. In addition, survival following a diagnosis of many cancers has increased in 
recent years due to earlier detection and improved survival, and these cancer survivors 
remain at risk (sometimes elevated risk) of developing a subsequent cancer [19]. The 
prevalence of patients diagnosed with multiple cancers is expected to increase [41].
Cancer registries serve a unique and important role in surveillance research. An examination 
of patterns of excess risk of subsequent cancers, particularly for cancers that occur in 
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different organ systems, can provide insight into potential causal mechanisms related to 
shared etiologies or genetic factors [19] or about excess risk related to prior cancer treatment 
[19, 42]. This type of research requires a large population base because events of interest 
may be relatively rare. For this reason, it is important that cancer registries adhere to a 
common protocol for enumerating primary cancers such that their data can be compared, 
combined, and examined over time. Clinicians may intuitively recognize a new primary 
cancer from that of a distant metastasis, extension, or recurrent cancer. However, it can be 
difficult to develop rules for identifying these cancers using routinely collected surveillance 
data. The identification of multiple primary cancers may reflect the quality and 
completeness of the surveillance data being reported to the cancer registry by hospitals, 
physicians’ offices, and laboratories; the training of hospital and registry staff to code the 
data and interpret the rules; and the follow-up of cancer patients to ascertain subsequent 
primary cancers. This may be particularly challenging for registries that use SEER rules as 
these rules are more complex, require more detailed information than IARC/IACR rules, and 
have changed over time.
Limitations
Cancer patients may move out of a registry’s catchment area before being diagnosed with a 
subsequent cancer. This may be more problematic for metropolitan area cancer registries and 
for some states more than others as the mobility and migration patterns of statewide 
populations in the USA are variable [43]. The two US federal cancer surveillance systems 
(the National Program of Cancer Registries [NPCR] [4] and SEER) are primarily case-based 
systems and registries do not report personal identifiers to their respective surveillance 
programs. Thus, it is difficult to identify inter-registry duplicate case reports or multiple 
primary cancer cases registered in the same cancer patient, but in different cancer registries 
[44]. This can result in over reporting of incidence cases and the under reporting of multiple 
primary cancers.
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Fig. 1. 
Number of cancers reported as a first primary cancer and number and percentage of cancers 
reported according to SEER and IACR/IACR multiple primary (MP) coding rules, by year 
of diagnosis (SEER: 1975–2011)
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Fig. 2. 
a–i Observed (dashed line) and modeled (solid line) age-standardized incidence rates by first 
(black) primary cancer and by SEER (light gray) and IARC/IACR (dark gray) multiple 
primaries for select cancers
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